Abstract Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for
amplification of insulin secretion when nutrients are given orally, as opposed to …

AIMS: Glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone mainly produced in the
post-prandial state, reduces blood glucose through the stimulation of insulin secretion and …

Abstract Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family
implicated in the control of appetite and satiety. GLP-1 has insulinotropic, insulinomimetic …

Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted
by the gut in response to food and helps in reducing post-prandial glucose exertion. It …

Major cardiovascular outcome trials and real-life observations have proven that glucagon-
like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 …

Aims/hypothesis Diabetic dyslipidaemia contributes to the excess morbidity and mortality in
patients with type 2 diabetes. Exogenous glucagon-like peptide 1 (GLP-1) lowers …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell
dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic …

Abstract Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family,
and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic …

Diabet. Med. 30, 289–299 (2013) Abstract Aims Glucagon‐like peptide‐1 receptor agonists
and inhibitors of dipeptidyl peptidase‐4 that increase glucagon‐like peptide‐1 plasma …